NRx Pharmaceuticals reports Q3 EPS (7c), consensus (11c)

As of September 30, the company had $8.9M in cash and cash equivalents. The company continues to believe cash on hand is sufficient to fund operations through potential delivery of the upcoming milestones described herein. “The Q3 represents a potential turning point for our company, as we are approaching our clinical trial enrollment goals for our partnered foundation product NRX-101, while opening new clinical initiatives in chronic pain, urinary tract infection, and NRX-100 for suicidal depression,” said Stephen Willard, CEO and Director of NRx Pharmaceuticals. “We have four upcoming milestones: in our core clinical trial of NRX-101, in the Department of Defense-funded clinical trial of DCS for chronic pain, in our program to open an IND and secure QIDP classification for NRX-101 in cUTI, and in our program to seek New Drug Approval for NRX-100 and establish that drug in a freshly-capitalized company. Achieving any one of those milestones has the potential to unlock substantial shareholder value, while success on more than one front has the potential to unlock exponential growth.”